Barclays PLC Bluebird Bio, Inc. Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Barclays PLC holds 252,062 shares of BLUE stock, worth $2.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
252,062
Previous 252,062 -0.0%
Holding current value
$2.21 Million
Previous $130,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$0.47 - $1.35 $86,764 - $249,216
184,605 Added 273.66%
252,062 $130,000
Q2 2024

Aug 14, 2024
SELL
$0.85 - $1.26 $56,841 - $84,258
-66,872 Reduced 49.78%
67,457 $66,000
Q1 2024

May 15, 2024
SELL
$0.91 - $1.75 $446,293 - $858,256
-490,432 Reduced 78.5%
134,329 $172,000
Q4 2023

Feb 15, 2024
SELL
$1.32 - $4.83 $4,031 - $14,750
-3,054 Reduced 0.49%
624,761 $862,000
Q3 2023

Nov 07, 2023
SELL
$3.02 - $4.05 $371,272 - $497,898
-122,938 Reduced 16.38%
627,815 $1.91 Million
Q2 2023

Aug 03, 2023
BUY
$2.79 - $5.03 $540,356 - $974,190
193,676 Added 34.77%
750,753 $2.47 Million
Q1 2023

May 04, 2023
SELL
$3.14 - $8.22 $45,530 - $119,190
-14,500 Reduced 2.54%
557,077 $1.77 Million
Q4 2022

Feb 13, 2023
SELL
$5.77 - $8.49 $175,938 - $258,877
-30,492 Reduced 5.06%
571,577 $3.96 Million
Q3 2022

Nov 03, 2022
BUY
$3.75 - $7.39 $1.83 Million - $3.61 Million
488,027 Added 427.94%
602,069 $3.81 Million
Q2 2022

Aug 12, 2022
BUY
$2.94 - $5.23 $19,853 - $35,318
6,753 Added 6.29%
114,042 $472,000
Q1 2022

May 16, 2022
BUY
$4.07 - $10.6 $102,983 - $268,211
25,303 Added 30.86%
107,289 $521,000
Q4 2021

Feb 14, 2022
SELL
$8.96 - $16.31 $105,280 - $191,642
-11,750 Reduced 12.54%
81,986 $819,000
Q3 2021

Nov 09, 2021
BUY
$11.24 - $21.0 $203,781 - $380,730
18,130 Added 23.98%
93,736 $1.79 Million
Q2 2021

Aug 13, 2021
BUY
$18.04 - $22.09 $476,256 - $583,176
26,400 Added 53.65%
75,606 $2.42 Million
Q1 2021

May 13, 2021
BUY
$16.59 - $33.89 $76,861 - $157,012
4,633 Added 10.39%
49,206 $1.48 Million
Q4 2020

Feb 11, 2021
SELL
$27.5 - $37.92 $1.13 Million - $1.56 Million
-41,065 Reduced 47.95%
44,573 $1.93 Million
Q3 2020

Nov 12, 2020
SELL
$34.44 - $43.75 $675,161 - $857,675
-19,604 Reduced 18.63%
85,638 $4.62 Million
Q2 2020

Aug 12, 2020
BUY
$27.12 - $45.97 $1.03 Million - $1.74 Million
37,873 Added 56.22%
105,242 $6.42 Million
Q1 2020

May 13, 2020
SELL
$26.16 - $63.5 $1.9 Million - $4.62 Million
-72,718 Reduced 51.91%
67,369 $3.1 Million
Q4 2019

Feb 10, 2020
BUY
$46.96 - $61.67 $5.11 Million - $6.71 Million
108,799 Added 347.73%
140,087 $12.3 Million
Q3 2019

Nov 14, 2019
BUY
$59.47 - $93.1 $1.49 Million - $2.33 Million
24,989 Added 396.71%
31,288 $2.87 Million
Q2 2019

Aug 14, 2019
BUY
$75.84 - $105.21 $84,334 - $116,993
1,112 Added 21.44%
6,299 $801,000
Q1 2019

May 15, 2019
SELL
$64.44 - $104.11 $250,800 - $405,196
-3,892 Reduced 42.87%
5,187 $816,000
Q4 2018

Feb 14, 2019
BUY
$59.1 - $93.26 $45,920 - $72,463
777 Added 9.36%
9,079 $901,000
Q3 2018

Nov 14, 2018
SELL
$88.86 - $117.49 $7.7 Million - $10.2 Million
-86,605 Reduced 91.25%
8,302 $1.21 Million
Q2 2018

Aug 14, 2018
SELL
$99.64 - $127.59 $1.09 Million - $1.4 Million
-10,978 Reduced 10.37%
94,907 $14.9 Million
Q1 2018

May 15, 2018
BUY
$105.8 - $150.94 $5.62 Million - $8.01 Million
53,099 Added 100.59%
105,885 $18.1 Million
Q4 2017

Feb 14, 2018
BUY
$81.25 - $130.7 $3.93 Million - $6.33 Million
48,408 Added 1105.71%
52,786 $9.4 Million
Q3 2017

Nov 14, 2017
BUY
$57.74 - $91.42 $252,785 - $400,236
4,378
4,378 $601,000

Others Institutions Holding BLUE

# of Institutions
150
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $677M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email